185 related articles for article (PubMed ID: 34314733)
1. In vitro inhibition of glutathione-S-transferase by dopamine and its metabolites, 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylacetic acid.
Crawford RA; Bowman KR; Cagle BS; Doorn JA
Neurotoxicology; 2021 Sep; 86():85-93. PubMed ID: 34314733
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
Goldstein DS; Jinsmaa Y; Sullivan P; Holmes C; Kopin IJ; Sharabi Y
J Pharmacol Exp Ther; 2016 Feb; 356(2):483-92. PubMed ID: 26574516
[TBL] [Abstract][Full Text] [Related]
3. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde.
Lamensdorf I; Eisenhofer G; Harvey-White J; Hayakawa Y; Kirk K; Kopin IJ
J Neurosci Res; 2000 May; 60(4):552-8. PubMed ID: 10797558
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
Vanle BC; Florang VR; Murry DJ; Aguirre AL; Doorn JA
Biochem Biophys Res Commun; 2017 Oct; 492(2):275-281. PubMed ID: 28830811
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal.
Florang VR; Rees JN; Brogden NK; Anderson DG; Hurley TD; Doorn JA
Neurotoxicology; 2007 Jan; 28(1):76-82. PubMed ID: 16956664
[TBL] [Abstract][Full Text] [Related]
6. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate.
Rees JN; Florang VR; Anderson DG; Doorn JA
Chem Res Toxicol; 2007 Oct; 20(10):1536-42. PubMed ID: 17887726
[TBL] [Abstract][Full Text] [Related]
7. Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Kopin IJ; Sharabi Y
J Neurochem; 2015 Apr; 133(1):14-25. PubMed ID: 25645689
[TBL] [Abstract][Full Text] [Related]
8. Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite.
Anderson DG; Florang VR; Schamp JH; Buettner GR; Doorn JA
Chem Res Toxicol; 2016 Jul; 29(7):1098-107. PubMed ID: 27268734
[TBL] [Abstract][Full Text] [Related]
9. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.
Mexas LM; Florang VR; Doorn JA
Neurotoxicology; 2011 Aug; 32(4):471-7. PubMed ID: 21514317
[TBL] [Abstract][Full Text] [Related]
10. Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.
Goldstein DS; Sullivan P; Cooney A; Jinsmaa Y; Sullivan R; Gross DJ; Holmes C; Kopin IJ; Sharabi Y
J Neurochem; 2012 Dec; 123(6):932-43. PubMed ID: 22906103
[TBL] [Abstract][Full Text] [Related]
11. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate.
Jinsmaa Y; Florang VR; Rees JN; Anderson DG; Strack S; Doorn JA
Chem Res Toxicol; 2009 May; 22(5):835-41. PubMed ID: 19388687
[TBL] [Abstract][Full Text] [Related]
12. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
[TBL] [Abstract][Full Text] [Related]
13. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
Lamensdorf I; Eisenhofer G; Harvey-White J; Nechustan A; Kirk K; Kopin IJ
Brain Res; 2000 Jun; 868(2):191-201. PubMed ID: 10854571
[TBL] [Abstract][Full Text] [Related]
14. Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA; do Nascimento LA; Eliezer D; Follmer C
ACS Chem Neurosci; 2019 Jan; 10(1):690-703. PubMed ID: 30352158
[TBL] [Abstract][Full Text] [Related]
15. Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
Vermeer LM; Florang VR; Doorn JA
Brain Res; 2012 Sep; 1474():100-9. PubMed ID: 22877852
[TBL] [Abstract][Full Text] [Related]
16. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
Goldstein DS; Sullivan P; Holmes C; Miller GW; Alter S; Strong R; Mash DC; Kopin IJ; Sharabi Y
J Neurochem; 2013 Sep; 126(5):591-603. PubMed ID: 23786406
[TBL] [Abstract][Full Text] [Related]
17. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
18. Impaired dopamine metabolism in Parkinson's disease pathogenesis.
Masato A; Plotegher N; Boassa D; Bubacco L
Mol Neurodegener; 2019 Aug; 14(1):35. PubMed ID: 31488222
[TBL] [Abstract][Full Text] [Related]
19. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.
Rees JN; Florang VR; Eckert LL; Doorn JA
Chem Res Toxicol; 2009 Jul; 22(7):1256-63. PubMed ID: 19537779
[TBL] [Abstract][Full Text] [Related]
20. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation.
Legros H; Dingeval MG; Janin F; Costentin J; Bonnet JJ
Neurotoxicology; 2004 Mar; 25(3):365-75. PubMed ID: 15019299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
